poisar

Stocks · News reference

HC Wainwright & Co. Maintains Buy on Oculis Holding, Raises Price Target to $39

Benzinga Newsdesk

HC Wainwright & Co. analyst Yi Chen maintains Oculis Holding (NASDAQ:OCS) with a Buy and raises the price target from $26 to $39.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

OCS
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Oculis Holding Ag

    Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day

    Oculis announced that CEO Riad Sherif will present Licaminlimab, a novel topical anti-TNFα candidate for TNFR1-mediated dry eye disease, at Eyecelerator @ AAO 2026 on October 8. The company's PREDICT-1 registrational trial is on track for topline readout around year-end. Oculis will also sponsor the Neuro-Ophthalmology Subspecialty Day, highlighting its commitment to advancing neuro-ophthalmology research and innovation.

    OCSOCSAW
  2. Zacks.Com

    Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?

    Halozyme Therapeutics shares rose 3.3% to $115.13 on strong volume, driven by investor optimism around its ENHANZE drug-delivery technology collaborations with major pharmaceutical companies. The company is expected to report quarterly earnings of $2.25 per share (+30.8% YoY) and revenues of $470.95 million (+32.9% YoY). With a 2.6% upward revision in consensus EPS estimates over the past 30 days and a Zacks Rank #2 (Buy) rating, analysts suggest monitoring the stock for potential continued strength.

    HALOOCSOCSAW